|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2509-2519.
Prepublished online as a Blood First Edition Paper on June 15, 2006; DOI 10.1182/blood-2006-03-010777.
 Previous Article | Table of Contents | Next Article 
REVIEW IN TRANSLATIONAL HEMATOLOGY
Current concepts in the pathophysiology and treatment of aplastic anemia
Neal S. Young,
Rodrigo T. Calado, and
Phillip Scheinberg
From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD.
Aplastic anemia, an unusual hematologic disease, is the paradigm of the human bone marrow failure syndromes. Almost universally fatal just a few decades ago, aplastic anemia can now be cured or ameliorated by stem-cell transplantation or immunosuppressive drug therapy. The pathophysiology is immune mediated in most cases, with activated type 1 cytotoxic T cells implicated. The molecular basis of the aberrant immune response and deficiencies in hematopoietic cells is now being defined genetically; examples are telomere repair gene mutations in the target cells and dysregulated T-cell activation pathways. Immunosuppression with antithymocyte globulins and cyclosporine is effective at restoring blood-cell production in the majority of patients, but relapse and especially evolution of clonal hematologic diseases remain problematic. Allogeneic stem-cell transplant from histocompatible sibling donors is curative in the great majority of young patients with severe aplastic anemia; the major challenges are extending the benefits of transplantation to patients who are older or who lack family donors. Recent results with alternative sources of stem cells and a variety of conditioning regimens to achieve their engraftment have been promising, with survival in small pediatric case series rivaling conventional transplantation results.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Maury, A. Bacigalupo, P. Anderlini, M. Aljurf, J. Marsh, G. Socie, R. Oneto, J. R. Passweg, and on behalf of the Severe Aplastic Anemia Working Pa
Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen
Haematologica,
September 1, 2009;
94(9):
1312 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Espinoza, H. Takamatsu, X. Lu, Z. Qi, and S. Nakao
Anti-moesin antibodies derived from patients with aplastic anemia stimulate monocytic cells to secrete TNF-{alpha} through an ERK1/2-dependent pathway
Int. Immunol.,
August 1, 2009;
21(8):
913 - 923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Brodsky
How I treat paroxysmal nocturnal hemoglobinuria
Blood,
June 25, 2009;
113(26):
6522 - 6527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Stotler, B. Eghtesad, E. Hsi, and B. Silver
Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept
Blood,
May 21, 2009;
113(21):
5365 - 5366.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. O. Pinto, T. Leblanc, D. Chamousset, G. Le Roux, B. Brethon, B. Cassinat, J. Larghero, J.-P. de Villartay, D. Stoppa-Lyonnet, A. Baruchel, et al.
Diagnosis of Fanconi anemia in patients with bone marrow failure
Haematologica,
April 1, 2009;
94(4):
487 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Omokaro, M. J. Desierto, M. A. Eckhaus, F. M. Ellison, J. Chen, and N. S. Young
Lymphocytes with Aberrant Expression of Fas or Fas Ligand Attenuate Immune Bone Marrow Failure in a Mouse Model
J. Immunol.,
March 15, 2009;
182(6):
3414 - 3422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Passweg and A. Tichelli
Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?
Haematologica,
March 1, 2009;
94(3):
310 - 312.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Hu, Y. Gu, Y. Wang, Y. Cong, X. Qu, and C. Xu
Increased CD4+ and CD8+ effector memory T cells in patients with aplastic anemia
Haematologica,
March 1, 2009;
94(3):
428 - 429.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-S. Delisle, L. Gaboury, M.-P. Belanger, E. Tasse, H. Yagita, and C. Perreault
Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-{gamma} receptor-deficient hosts
Blood,
September 1, 2008;
112(5):
2111 - 2119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Montane, L. Ibanez, X. Vidal, E. Ballarin, R. Puig, N. Garcia, J.-R. Laporte, and the Catalan Group for the Study of Agranulocytosis
Epidemiology of aplastic anemia: a prospective multicenter study
Haematologica,
April 1, 2008;
93(4):
518 - 523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E. Solomou, K. Rezvani, S. Mielke, D. Malide, K. Keyvanfar, V. Visconte, S. Kajigaya, A. J. Barrett, and N. S. Young
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia
Blood,
September 1, 2007;
110(5):
1603 - 1606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Trisal, A. Nademanee, S. K. Lau, and F. W. Grannis Jr
Thymoma-Associated Severe Aplastic Anemia Treated With Surgical Resection Followed by Allogeneic Stem-Cell Transplantation
J. Clin. Oncol.,
August 1, 2007;
25(22):
3374 - 3375.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-i. Sawada, M. Hirokawa, N. Fujishima, M. Teramura, M. Bessho, K. Dan, H. Tsurumi, S. Nakao, A. Urabe, M. Omine, et al.
Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group
Haematologica,
August 1, 2007;
92(8):
1021 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E. Solomou, F. Gibellini, B. Stewart, D. Malide, M. Berg, V. Visconte, S. Green, R. Childs, S. J. Chanock, and N. S. Young
Perforin gene mutations in patients with acquired aplastic anemia
Blood,
June 15, 2007;
109(12):
5234 - 5237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Sukati, H. G. Watson, S. J. Urbaniak, and R. N. Barker
Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura
Blood,
May 15, 2007;
109(10):
4528 - 4538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Maury, M.-L. Balere-Appert, Z. Chir, J.-M. Boiron, C. Galambrun, K. Yakouben, P. Bordigoni, A. Marie-Cardine, N. Milpied, J. Kanold, et al.
Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient
Haematologica,
May 1, 2007;
92(5):
589 - 596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Scheinberg, S. H. Fischer, L. Li, O. Nunez, C. O. Wu, E. M. Sloand, J. I. Cohen, N. S. Young, and A. John Barrett
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
Blood,
April 15, 2007;
109(8):
3219 - 3224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, F. M. Ellison, M. A. Eckhaus, A. L. Smith, K. Keyvanfar, R. T. Calado, and N. S. Young
Minor Antigen H60-Mediated Aplastic Anemia Is Ameliorated by Immunosuppression and the Infusion of Regulatory T Cells
J. Immunol.,
April 1, 2007;
178(7):
4159 - 4168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bacigalupo
Aplastic Anemia: Pathogenesis and Treatment
Hematology,
January 1, 2007;
2007(1):
23 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Bagby and G. Meyers
Bone Marrow Failure as a Risk Factor for Clonal Evolution: Prospects for Leukemia Prevention
Hematology,
January 1, 2007;
2007(1):
40 - 46.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
